Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?

Eye (2023)Cite this article

Subjects

Biosimilar anti-VEGFs are emerging as a wave with a series of biosimilar ranibizumab approvals in the last 2 years across the globe by various regulatory agencies including the United States Food and Drug Administration (US-FDA) and European Medical Agency (EMA) [1]. Furthermore, multiple biosimilar aflibercept molecules are in the final stages of regulatory approval process [2]. Once the aflibercept patent expires, these molecules will be available for clinical use.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab-a global update. Eye. 2023;37:200–2.

    Article  PubMed  Google Scholar 

  2. Sharma A, Parachuri N, Kumar N, Bandello B, Kuppermann BD. Emerging biosimilars for retinal diseases. Expert Rev Ophthalmol. 2022;17:383–6.

    Article  CAS  Google Scholar 

  3. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/125156s0000_LucentisTOC.cfm#:~:text=Approval%20Date%3A%2006%2F30%2F2006. Accessed June 2023

  4. https://www.gene.com/media/press-releases/14708/2018-03-21/fda-approves-genentechs-lucentis-ranibiz#:~:text=The%20Lucentis%200.5%20mg%20PFS,myopic%20choroidal%20neovascularization%20(mCNV). Accessed June 2023

  5. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125387s0000toc.cfm. Accessed June 2023

  6. https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injection-prefilled-syringe. Accessed June 2023

  7. https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-beovu-offering-wet-amd-patients-vision-gains-and-greater-fluid-reductions-vs-aflibercept. Accessed June 2023

  8. https://www.ophthalmologyweb.com/1315-News/586982-FDA-Approves-BEOVU-for-the-Treatment-of-Diabetic-Macular-Edema/#:~:text=Novartis%20remains%20committed%20to%20bringing,fewer%20steps%20than%20the%20vial. Accessed June 2023

  9. https://www.gene.com/media/press-releases/14943/2022-01-28/fda-approves-genentechs-vabysmo-the-firs. Accessed June 2023

  10. https://delta.larvol.com/Products/?ProductId=f3156ea9-686c-49c0-a5c7-09dab6ea60ca. Accessed June 2023

  11. Dingerkus VLS, Somfai GM, Kinzl S, Orgül SI, Becker MD, Heussen FM. Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes. Sci Rep. 2022;12:18136.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Funding

BDK acknowledges an unrestricted grant to the Gavin Herbert Eye Institute from Research to Prevent Blindness.

Author information

Authors and Affiliations

  1. Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, Tamil Nadu, India

    Ashish Sharma

  2. Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel

    Anat Loewenstein

  3. Department of Vitreoretina, Sankara eye Hospital, Coimbatore, Tamil Nadu, India

    Nikulaa Parachuri

  4. Madhavi Netralaya, Ara, Bihar, India

    Nilesh Kumar

  5. Intas Pharmaceuticals, Ahmedabad, Gujarat, India

    Alok Rasal

  6. University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy

    Francesco Bandello

  7. Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA

    Baruch D. Kuppermann

Authors
  1. Ashish Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anat Loewenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nikulaa Parachuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nilesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alok Rasal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesco Bandello
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Baruch D. Kuppermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS: conception, analysis, drafting, integrity check, final approval. AL, NP, NK, AR, BDK; drafting, revision, analysis, integrity check.

Corresponding author

Correspondence to Ashish Sharma.

Ethics declarations

Competing interests

AS: CONSULTANT: for Novartis, Allergan, Bayer, Lupin and Intas, Speaker fee Biogen. AL: CONSULTANT: Allergan, Novartis, Roche, Notal Vision, Fiorsightslabs, Beyeonics, Bayer Health Care. AR: Employee Intas Pharmaceuticals Ltd. FB: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK: CLINICAL RESEARCH:, Alimera, Allegro, Allergan, Apellis, Boehringer Ingelheim, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron; CONSULTANT: Alimera, Allegro, Allergan/AbbVie, Boehringer Ingelheim, Clearside, Coherus, EyeBio, Eyedaptic, Galimedix, Genentech, Glaukos, IvericBio, jCyte, Novartis, Ocular Therapeutix, Regeneron, Revana, Theravance Biopharma. The other authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Loewenstein, A., Parachuri, N. et al. Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?. Eye (2023). https://doi.org/10.1038/s41433-023-02698-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1038/s41433-023-02698-3

This article is cited by

Search

Advanced search

Quick links